What is Korro Bio Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Korro Bio's cash to debt ratio for the quarter that ended in Jun. 2023 was 2.08.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Korro Bio could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.
The historical rank and industry rank for Korro Bio's Cash-to-Debt or its related term are showing as below:
KRRO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 5 Med: 17.65 Max: No Debt
Current: 5
During the past 3 years, Korro Bio's highest Cash to Debt Ratio was No Debt. The lowest was 5.00. And the median was 17.65.
Korro Bio Cash-to-Debt Historical Data
The historical data trend for Korro Bio's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Korro Bio Cash-to-Debt Chart
|
Korro Bio Annual Data
|
|
Trend |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
No Debt |
17.65 |
5.00 |
|
Korro Bio Semi-Annual Data
|
|
Dec21 |
Jun22 |
Dec22 |
Jun23 |
Dec23 |
| Cash-to-Debt |
No Debt |
N/A |
17.65 |
2.08 |
5.00 |
Competitive Comparison of Korro Bio's Cash-to-Debt
For the Biotechnology subindustry, Korro Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korro Bio's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Korro Bio's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Korro Bio's Cash-to-Debt falls into.
Korro Bio Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Korro Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Korro Bio's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korro Bio (Korro Bio) Business Description
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
| David L. Lucchino |
director, officer: President and CEO |
C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801 |
| Rick Yang |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Edward T Mathers |
10 percent owner |
C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Nessan Bermingham |
director |
890 WINTER STREET, WALTHAM MA 02451 |
| Atlas Venture Associates Xi, Llc |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| New Enterprise Associates 17, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea Partners 17, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea 17 Gp, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Atlas Venture Fund Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Opportunity Fund Ii, L.p. |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity Ii, Llc |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity Ii, Lp |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Steve Colletti |
officer: Chief Scientific Officer |
C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139 |
| Shelby J. Walker |
officer: See Remarks |
C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139 |
Korro Bio (Korro Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRRO has been successfully added to your